Identification and Characterisation of a cyclic di-GMP-specific Diguanylate Cyclase and Phosphodiesterase Genes in Klebsiella Pneumoniae MBB9
Abstract
Bis-(3โโ5โ)-cyclic-dimeric guanosine monophosphate (c-di-GMP) is a bacterial second messenger known to mediate the regulation of multiple cellular processes, including bacterial adhesion and biofilm formation, bacterial motility, and control the virulence of bacterial pathogens. In many bacteria, the second messenger c-di-GMP, an intracellular signalling molecule, plays a key role in the lifestyle changes and controls the transition between the motile planktonic and sessile biofilm lifestyles. The intracellular levels of c-di-GMP are controlled by c-di-GMP synthesis and degradation catalyzed by diguanylate cyclase (DGC) and phophodiesterase (PDE) enzymes. The GGDEF protein domain synthesizes cyclic di-GMP, whereas the EAL and HD-GYP domains are involved in cyclic di-GMP hydrolysis. Various bacteria contain many copies of these proteins with a diverse organizational structure that highlights the complex regulatory mechanisms of this signaling network. The whole genome of Klebsiella pneumoniae MBB9, recovered from river-stones collected from the Porter Brook, Sheffield, was sequenced and compared to K. pneumoniae 342 to identify DGCs and PDEs and analyze the domain structure of such proteins. Klebsiella pneumoniae MBB9 harboured multiple copies of proteins with GGDEF and EAL domains, most of these were linked to sensory domains and were found to possess 11 genes with GGDEF domains, 11 genes with EAL domains, and 6 genes with both GGDEF and EAL domains. Thirty-nine percent of these proteins contained the GGDEF sequence motif, whereas 39% had EAL sequence motif, and 21 % were hybrid proteins containing both GGDEF and EAL domains. The majority of GGDEF domains are catalytically active as they have an intact conserved A site, whereas all EAL domains have c-di-GMP PDE activity except BluF_2 and YahA proteins.
Full text article
References
2. Guadagni S, Catarci M, Kinoshita Tยด et al. Causes of death and recurrence after surgery for early gastric cancer. World J. Surg. 21(4), 434โ439 (1997).
3. Yoshikawa K, Kitaoka H. Bone metastasis of gastric cancer. Jpn J. Surg. 13, 173โ176 (1983).
4. Nishidoi H and Koga S: Clinicopathological study of gastric cancer with bone metastasis. Gan To Kagaku Ryoho 14: 1717 1722, 1987 (In Japanese).
5. Choi CW, Lee DS, Chung JK, Lee MC, Kim NK, Choi KW and Koh CS: Evaluation of bone metastases by Tc 99m MDP imaging in patients with stomach cancer. Clin Nucl Med 20: 310 314, 1995.
6. Nielsen OS, Munro AJ and Tannock IF: Bone metastases: Pathophysiology and management policy. J Clin Oncol 9: 509 524, 1991.
7. Mundy GR: Metastasis to bone: Causes, consequences and thera peutic opportunities. Nat Rev Cancer 2: 584 593, 2002.
8. Coleman RE: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12 (Suppl): 6243S 6249S, 2006.
9. Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, Dreicer R, Kuross SA, Lipton A and Seaman JJ: Zoledronic acid reduces skeletal related events in patients with osteolytic metastases. Cancer 91: 1191 1200, 2001.
10. Riihimaki M, Hemminki A, Sundquist K, Sundquist J and Hemminki K: Metastatic spread in patients with gastric cancer. Oncotarget 7: 52307 52316, 2016.
11. Nakamura K, Tomioku M, Nabeshima K et al. Clinicopathologic features and clinical outcomes of gastric cancer patients with bone metastasis. Tokai J. Exp. Clin. Med. 39(4), 193โ198 (2014).
12. Zhang H, Zhang RP, Li FX et al. Clinicopathological characteristics and prognostic analysis of bone metastasis in gastric cancer patients. Zhonghua Wei Chang Wai Ke Za Zhi 16(4), 354โ357 (2013).
13. Jota M, Yutaka K, Yoichi M et al. Clinical outcomes and prognostic factors for gastric cancer patients with bone metastasis. World J Surg Oncol. 2017 Jan 6;15(1):8.
14. Wen L, Li YZ, Zhang J et al. Clinical analysis of bone metastasis of gastric cancer: incidence,clinicopathological features and survival. Future Oncol. 2019 Jul;15(19):2241-2249.
15. Lim SM, Kim YN, Park KH et al. Bone alkaline phosphatase as a surrogate marker of bone metastasis in gastric cancer patients. BMC Cancer 16, 385 (2016).
16. Rosen LS, Gordon D, Tchekmedyian NS et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non-small-cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 100(12), 2613โ2621 (2004).